Kai-Hsin Chang, Ph.D., is a cell and gene therapy leader focused on advancing genetic medicines and regenerative therapies from discovery through translational development. She currently serves as Head of Drug Development and Senior Vice President at GC Therapeutics, where she leads drug development and translational research for therapies built on the company’s TFome™️ cell programming platform.

Prior to joining GC Therapeutics, Kai-Hsin held leadership positions at Editas Medicine, where she led genome editing and engineered cell therapy programs from early research through preclinical development. She is also a co-inventor of reni-cel, an investigational autologous gene-edited cell therapy for sickle cell disease and beta thalassemia. Her expertise spans stem cell biology, hematology, genome engineering, and translational drug development.

Kai-Hsin was trained as an experimental hematologist and stem cell biologist, and has dedicated her career to developing innovative therapies for patients with serious diseases.